The outcomes of Polish patients with advanced BRAF-positive melanoma treated with vemurafenib in a safety clinical trial

AIM OF THE STUDY: The BRAF inhibitor vemurafenib has improved progression-free survival and overall survival in patients with BRAFV600-mutation-positive metastatic melanoma. Here we present the results of an open-label safety study with vemurafenib in patients with metastatic melanoma enrolled in Po...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Contemp Oncol (Pozn)
Main Authors: Rutkowski, Piotr, Kozak, Katarzyna, Mackiewicz, Jacek, Krzemieniecki, Krzysztof, Nawrocki, Sergiusz, Wasilewska-Teśluk, Ewa, Kwinta, Łukasz, Wysocki, Piotr, Koseła-Paterczyk, Hanna, Świtaj, Tomasz
Format: Artigo
Jezik:Inglês
Izdano: Termedia Publishing House 2015
Teme:
Original Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4631301/
https://ncbi.nlm.nih.gov/pubmed/26557775
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/wo.2015.54082
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki